Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.

doi:10.1038/clpt.2014.126

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.

Clinical pharmacology and therapeutics - 1 Sept 2014

Guillemette C, Lévesque É, Rouleau M

Abstract excerpt

Glucuronidation by uridine diphospho-glucuronosyltransferase enzymes (UGTs) is a major phase II biotransformation pathway and, complementary to phase I metabolism and membrane transport, one of the most important cellular defense mechanisms responsible for the inactivation of therapeutic drugs, other xenobiotics, and endogenous molecules. Interindividual variability in UGT pathways is significant and may have...

Topics

Drug Interactions
Drug-Related Side Effects and Adverse Reactions
Genetic Variation
Genotype
Glucuronides
Glucuronosyltransferase
Humans
Isoenzymes
Metabolic Detoxication, Phase II
Pharmacogenetics
Pharmacokinetics
Phenotype
Precision Medicine
Risk Assessment
Risk Factors

Source

Open in PubMed

Identifiers

PMID: 24922307
DOI: 10.1038/clpt.2014.126

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics